Combined Nortriptyline and Transdermal Nicotine for Smoking Cessation

• Status: Completed
• Trial end date: 2003-01-01
• Target enrollment: 0
• Participant gender: All

Summary

Treatment of smokers with a tricyclic antidepressant, nortriptyline, can reduce tobacco withdrawal symptoms and increases long term cessation rates when combined with transdermal nicotine and a behavioral cessation programs. The study is a placebo-controlled, randomized, parallel group trial in which smokers aged 18-70 will be subject to the combination of oral and patch treatments.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: US Department of Veterans Affairs; VA Office of Research and Development
• Treatments: Nicotine; Nortriptyline

Criteria

Inclusion Criteria:

• Aged 18-70,

• smoking > 10 cigarettes per day,

• no current major depression,

• no concurrent psychiatric medications

Exclusion Criteria: